Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system

References

• US Institute of MedicineRelieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and ResearchWashingtonNational Academies Press2011
   Google Scholar
• US Food Drug AdministrationAbuse-deterrent opioids — evaluation and labeling: guidance for industry2015 Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdfAccessed April 26, 2017
   Google Scholar
• BrennanMJUpdate on prescription extended-release opioids and appropriate patient selectionJ Multidiscip Healthc2013626528023900563
   PubMedGoogle Scholar
• ArgoffCESilversheinDIA comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needsMayo Clin Proc200984760261219567714
   PubMed Web of Science ®Google Scholar
• RauckRLWhat is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical reviewPain Pract20099646847919874536
   PubMed Web of Science ®Google Scholar
• JohnsonREFudalaPJPayneRBuprenorphine: considerations for pain managementJ Pain Symptom Manage200529329732615781180
   PubMed Web of Science ®Google Scholar
• PergolizziJAloisiAMDahanACurrent knowledge of buprenorphine and its unique pharmacological profilePain Pract201010542845020492579
   PubMed Web of Science ®Google Scholar
• LikarRKayserHSittlRLong-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow up study in patients from three short-term clinical trialsClin Ther200628694395216860176
   PubMed Web of Science ®Google Scholar
• Butrans [prescribing information]Stamford (CT)Purdue Pharma LP2014
   Google Scholar
• SteinerDMuneraCHaleMRipaSLandauCEfficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind studyJ Pain201112111163117321807566
   PubMed Web of Science ®Google Scholar
• SteinerDJSitarSWenWEfficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled studyJ Pain Symptom Manage201142690391721945130
   PubMed Web of Science ®Google Scholar
• LandauCJCarrWDRazzettiAJSesslerNEMuneraCRipaSRBuprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia studyClin Ther200729102179219318042474
   PubMed Web of Science ®Google Scholar
• MuneraCDrehoblMSesslerNELandauCA randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritisJ Opioid Manage201063193202
   PubMedGoogle Scholar
• BreivikJLjosaaTMStengaard-PedersenKA 6-months, randomized, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioidsScand J Pain20101122141
   PubMedGoogle Scholar
• ConaghanPGO’BrienCMWilsonMSchofieldJPTransdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trialOsteoarthritis Cartilage201119893093821477658
   PubMed Web of Science ®Google Scholar
• GordonACallaghanDSpinkDBuprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phaseClin Ther201032584486020685494
   PubMed Web of Science ®Google Scholar
• GordonARashiqSMoulinDEBuprenorphine transdermal system for opioid therapy in patients with chronic low back painPain Res Manag201015316917820577660
   PubMed Web of Science ®Google Scholar
• JamesIGO’BrienCMMcDonaldCJA randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis painJ Pain Symptom Manage201040226627820541900
   PubMed Web of Science ®Google Scholar
• KarlssonMBerggrenACEfficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 μg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority studyClin Ther200931350351319393841
   PubMed Web of Science ®Google Scholar
• GutsteinHBAkilHOpioid analgesicsBruntonLLGoodman and Gilman’s Pharmacological Basis of Therapeutics11th edNew YorkMcGraw-Hill2006547590
   Google Scholar
• HuangPKehnerGBCowanALiu-ChenLYComparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonistJ Pharmacol Exp Ther2001297268869511303059
   PubMed Web of Science ®Google Scholar
• RaffaRBDingZExamination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonistAcute Pain200793145152
   Google Scholar
• KögelBChristophTStrassburgerWFriderichsEInteraction of μ-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in miceEur J Pain20059559961116139189
   PubMed Web of Science ®Google Scholar
• WalshSLEissenbergTThe clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinicDrug Alcohol Depend2003702 SupplS13S27
   PubMed Web of Science ®Google Scholar
• KressHGClinical update on the pharmacology, efficacy and safety of transdermal buprenorphineEur J Pain200913321923018567516
   PubMed Web of Science ®Google Scholar
• GreenwaldMKComerSDFiellinDABuprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policyDrug Alcohol Depend201414411125179217
   PubMed Web of Science ®Google Scholar
• HuberERobinsonRCNoeCEVan NessOWho benefits from chronic opioid therapy? Rethinking the question of opioid misuse riskHealthcare (Basel)201642E2927417617
   PubMedGoogle Scholar
• BohnertASBValensteinMBairMJAssociation between opioid prescribing patterns and opioid overdose-related deathsJAMA2011305131315132121467284
   PubMed Web of Science ®Google Scholar
• PortenoyRKBennettDSRauckRPrevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer painJ Pain20067858359116885015
   PubMed Web of Science ®Google Scholar
• ChouRFancuilloFinePGClinical guidelines for the use of chronic opioid therapy in chronic noncancer painJ Pain200910211313019187889
   PubMed Web of Science ®Google Scholar
• DowellDHaegerichTMChouRCDC guideline for prescribing opioids for chronic pain: United States, 2016MMWR Recomm Rep2016651149
   PubMed Web of Science ®Google Scholar
• AurilioCPaceMCPotaVOpioids switching with transdermal systems in chronic cancer painJ Exp Clin Cancer Res2009286119422676
   PubMed Web of Science ®Google Scholar
• BöhmeKLikarREfficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain: a randomised, double-blind, placebo-controlled studyPain Clin2003152193202
   Web of Science ®Google Scholar
• de BarutellCGonzalez-EscaladaJEfficacy and safety of buprenorphine TDS in conjunction with oral tramadol or morphine as rescue medication in the treatment of 390 patients with chronic pain: a summary of two retrospective Spanish multicenter studiesJ Appl Ther Res2007621424
   Google Scholar
• FreyeEAnderson-HillemacherARitzdorfILevyJVOpioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patientsPain Pract20077212312917559481
   PubMedGoogle Scholar
• MentenJCarpentierIDeschutterHNuytsSVan BeekKThe use of transdermal buprenorphine to relieve radiotherapy related pain in head and neck cancer patientsCancer Invest201331641242023758187
   PubMed Web of Science ®Google Scholar
• MercadanteSVillariPFerreraPSafety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphineJ Pain Symptom Manage200632217517916877185
   PubMed Web of Science ®Google Scholar
• MercadanteSPorzioGFulfaroFSwitching from transdermal drugs: an observational “n of 1” study of fentanyl and buprenorphineJ Pain Symptom Manage200734553253817629666
   PubMed Web of Science ®Google Scholar
• MercadanteSCasuccioATirelliWGiarratanoAEquipotent doses to switch from high doses of opioids to transdermal buprenorphineSupport Care Cancer200917671571819104845
   PubMed Web of Science ®Google Scholar
• MordarskiSEfficacy and safety of buprenorphine in patients receiving haemodialysisJ Appl Ther Res2009724651
   Google Scholar
• NadezhdaAOsipovaNAbuzarovaGTransdermal buprenorphine for the treatment of chronic pain syndrome in oncology patientsJ Appl Ther Res2009726572
   Google Scholar
• PaceMCPassavantiMBGrellaEBuprenorphine in long-term control of chronic pain in cancer patientsFront Biosci2007121291129917127381
   PubMed Web of Science ®Google Scholar
• PoulainPDenierWDoumaJEfficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer painJ Pain Symptom Manage200836211712518411010
   PubMed Web of Science ®Google Scholar
• RuggieroACocciaPArenaREfficacy and safety of transdermal buprenorphine in the management of children with cancer-related painPediatr Blood Cancer201360343343723034996
   PubMed Web of Science ®Google Scholar
• SettiTSanfilippoFLeykinYTransdermal buprenorphine for postoperative pain control in gynecological surgery: a prospective randomized studyCurr Med Res Opin201228101597160822876835
   PubMed Web of Science ®Google Scholar
• SittlRGriessingerNLikarRAnalgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trialClin Ther200325115016812637117
   PubMed Web of Science ®Google Scholar
• SorgeJSittlRTransdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled studyClin Ther200426111808182015639693
   PubMed Web of Science ®Google Scholar
• ZarthRComparison of buprenorphine, morphine sulfate, and fentanyl citrate as rescue medication for breakthrough pain in cancer patientsJ Appl Ther Res2008641519
   Google Scholar
• JohnsonREStrainECAmassLBuprenorphine: how to use it rightDrug Alcohol Depend2003702 SupplS59S7712738351
   PubMed Web of Science ®Google Scholar
• StrainECPrestonKLLiebsonIAAcute effects of buprenorphine, hydromorphone and naloxone in methadone maintained volunteersJ Pharmacol Exp Ther199226139859931376362
   PubMed Web of Science ®Google Scholar
• StrainECPrestonKLLiebsonIABuprenorphine effects in methadone-maintained volunteers: effects at two hours after methadoneJ Pharmacol Exp Ther199527226286387853176
   PubMed Web of Science ®Google Scholar
• WalshSLJuneHLSchuhKJEffects of buprenorphine and methadone in methadone-maintained subjectsPsychopharmacology (Berl)199511932682767675960
   PubMed Web of Science ®Google Scholar
• SchuhKJWalshSLBigelowGEBuprenorphine, morphine and naloxone effects during ascending morphine maintenance in humansJ Pharmacol Exp Ther199627828368468768738
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse TreatmentClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: A Treatment Improvement Protocol (TIP) 40Rockville (MD)US Department of Health and Social Services2004
   Google Scholar
• Suboxone [package insert]Slough (UK)Reckitt Benckiser Pharmaceuticals2014
   Google Scholar
• Subutex [package insert]Slough (UK)Reckitt Benckiser Pharmaceuticals2014
   Google Scholar
• Bunavail [package insert]RaleighBioDelivery Sciences International2014
   Google Scholar
• Zubsolv [package insert]Morristown (NJ)Orexo US2014
   Google Scholar
• NathRPUptonRAEverhartETBuprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulationsJ Clin Pharmacol199939561962310354966
   PubMed Web of Science ®Google Scholar
• MendelsonJUptonRAEverhartETJacobPJonesRTBioavailability of sublingual buprenorphineJ Clin Pharmacol199737131379048270
   PubMed Web of Science ®Google Scholar
• GreenwaldMKJohansonCEMoodyDEEffects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteersNeuropsychopharmacology200328112000200912902992
   PubMed Web of Science ®Google Scholar
• CowanAFriderichsStrassburgerWRaffaRBBasic pharmacology of buprenorphineBuddKRaffaBRBuprenorphine: The Unique Opioid AnalgesicStuttgartThieme2005321
   Google Scholar
• Electronic Medicines CompendiumTranstec 35, 52.5, and 70 micrograms transdermal patch2015 Available from: http://www.medicines.org.uk/emc/medicine/8864Accessed April 26, 2017
   Google Scholar
• LikarRTransdermal buprenorphine in the management of persistent pain: safety aspectsTher Clin Risk Manag20062111512518360586
   PubMedGoogle Scholar